Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
Trial record 10 of 16 for:    celiac | Open Studies | United States

Imaging the Duodenum Using an Optical Frequency Domain Imaging OFDI Capsule

This study is currently recruiting participants. (see Contacts and Locations)
Verified October 2016 by Massachusetts General Hospital
Sponsor:
Information provided by (Responsible Party):
Guillermo Tearney, Massachusetts General Hospital
ClinicalTrials.gov Identifier:
NCT02202681
First received: June 12, 2014
Last updated: October 27, 2016
Last verified: October 2016
  Purpose

The study is being done to assess the tolerability and feasibility of a tethered OFDI capsule to image the duodenum.

A total of 24 subjects will be asked to swallow the tethered capsule, while they are awake and unsedated and ask for their feedback. Images will be taken using the OFDI system while the capsule travels from the esophagus into the stomach and into the duodenum.


Condition Intervention Phase
Celiac Disease
Device: OFDI Capsule
Phase 1

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Official Title: Pilot Study for Imaging of the Duodenum Using an OFDI Capsule

Resource links provided by NLM:


Further study details as provided by Massachusetts General Hospital:

Primary Outcome Measures:
  • Tolerability of OFDI Imaging in subjects swallowing the OFDI capsule [ Time Frame: Images will be acquired during the OFDI imaging session which should on average take anywhere from 30 minutes to 2 hours. ] [ Designated as safety issue: No ]
    After participating in the study, the subject will be asked for feedback about tolerability of the procedure using a questionnaire.


Secondary Outcome Measures:
  • Feasibility of OFDI Imaging in subjects swallowing the OFDI capsule [ Time Frame: Images will be acquired during the OFDI imaging session which should on average take anywhere from 30 minutes to 2 hours ] [ Designated as safety issue: No ]
    An investigator will assess the quality of the recorded images and movies obtained with each exam after the imaging is completed.


Estimated Enrollment: 24
Study Start Date: August 2013
Estimated Study Completion Date: October 2017
Estimated Primary Completion Date: October 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: OFDI Capsule Imaging
Subject will swallow the OFDI Capsule and imaging will be performed using the OFDI system.
Device: OFDI Capsule
Imaging of the duodenum with the OFDI capsule and system

Detailed Description:

Subjects including healthy volunteers as well as patients with Celiac disease will be recruited and asked to swallow the OFDI capsule while being awake and unsedated. The capsule is attached to a tether which allows the operator to control as well as navigate the capsule as it progresses down the esophagus, through the stomach and into the duodenum using natural propulsive force called peristalsis.

As the capsule progresses, multiple 2-dimensional cross sectional images of the duodenum are acquired. Images are analyzed at a later stage.

  Eligibility

Ages Eligible for Study:   16 Years and older   (Child, Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Subject must be over 18 years for healthy volunteers
  • Subjects must be over 16 years for patients with Celiac disease
  • Subject must be able to give informed consent

Exclusion Criteria:

  • Subjects with an inability to swallow pills or capsules.
  • Subjects with esophageal or intestinal fistulas.
  • Subjects with known esophageal or intestinal strictures resulting in a luminal diameter smaller than the diameter of the capsule.
  • Subjects with a history of intestinal Crohn's disease.
  • Women who are pregnant.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02202681

Contacts
Contact: Guillermo Tearney, MD., PhD 617-724-2979 gtearney@partners.org
Contact: Mireille Rosenberg, PhD 617-726-4422 mrosenberg@partners.org

Locations
United States, Massachusetts
Massachusetts General Hospital Recruiting
Boston, Massachusetts, United States, 02114
Sponsors and Collaborators
Massachusetts General Hospital
Investigators
Principal Investigator: Guillermo Tearney, MD., PhD Massachusetts General Hospital
  More Information

Responsible Party: Guillermo Tearney, Principal Investigator, Massachusetts General Hospital
ClinicalTrials.gov Identifier: NCT02202681     History of Changes
Other Study ID Numbers: 2013-P-001405 
Study First Received: June 12, 2014
Last Updated: October 27, 2016
Health Authority: United States: Institutional Review Board
Individual Participant Data  
Plan to Share IPD: No

Keywords provided by Massachusetts General Hospital:
Duodenum
Optical Frequency Domain Imaging (OFDI)
Optical Coherence Tomography
Imaging
Celiac Disease

Additional relevant MeSH terms:
Celiac Disease
Malabsorption Syndromes
Intestinal Diseases
Gastrointestinal Diseases
Digestive System Diseases
Metabolic Diseases

ClinicalTrials.gov processed this record on December 02, 2016